After optimizing the overall structure of Ziqiang Sheng, personnel change messages often occur. Recently, Larry Jones, Global Vice President of Medical Technology and Group Chief Information Officer at Johnson&Johnson, announced his decision to resign. He will retire from Johnson&Johnson Medical Devices, and details such as when he will officially resign or who will take over are still unknown. 35 year veteran resigns, Johnson&Johnson personnel changes frequently Larry Jones is an experienced veteran at Johnson&Johnson Medical, having served for 35 years. During his tenure at Johnson&Johnson’s Medical Devices division, Larry Jones was particularly dedicated to driving innovation in the fields of oncology, orthopedics, cardiovascular and general surgery, and revolutionizing digital surgical connectivity solutions through advanced technologies such as surgical robots and machine learning platforms. Larry Jones has served as the trans regional global CIO of Janssen Pharmaceuticals for more than six years. He is the executive member of the Johnson African ...
Recently, Larry Jones, Global Vice President and Group Chief Information Officer of Medical Technology at Johnson&Johnson (NYSE: JNJ), will leave the world’s second-largest medical device manufacturer. He will retire from Johnson&Johnson’s medical device business. The details of when and when the official resignation will take place, or who will take over, are still unknown. 01. Retirement of Group Chief Information Officer Recently, Larry Jones announced that he will retire from Johnson&Johnson’s medical device business. When asked when he will officially resign or if someone will replace him, he said he will share more details when the information becomes public. Johnson&Johnson Medical Technology did not respond to further information requests. Jones is a goal oriented leader who achieves transformational change through key principles such as business process integration, agile methods, and next-generation technology solutions. He focuses on driving digital surgical connectivity solutions for Johnson&Johnson’s oncology, orthopedics, cardiovascular, and general surgery robots ...
Not long ago, Larry Jones, Global Vice President and Group Chief Information Officer of Johnson & Johnson MedTech, announced his decision to resign. On the LinkedIn platform, Jones recalled fondly: “Looking back on the 35 glorious years spent at Johnson & Johnson, my heart is filled with deep nostalgia for the extraordinary times we have gone through together.” During his tenure in Johnson & Johnson’s medical device department, Jones was particularly committed to promoting the company’s innovation in oncology, orthopedics, cardiovascular and general surgery, and realizing the innovation of digital surgical connection solutions through advanced technologies such as surgical robots and machine learning platforms. As a senior technology executive, Jones has rich leadership experience. During his decades in office, he has led many major projects in Johnson & Johnson’s pharmaceutical and medical device departments, including the recent three-year, $200 million global digital transformation plan. According to LinkedIn information, Jones is ...
On October 28, 2024, Medtronic announced the appointment of Dr. Matthew Kroh as Chief Medical Officer for Advanced and General Surgery Technologies. Dr. Matthew Crowe is the Vice President of Innovation and Technology at the Cleveland Clinic Digestive Disease and Surgery Institute. He is the director of the Department of General Surgery, Endoscopic Surgery, and Foreintestinal Surgery. 01. Surgical Laparoscopic Specialist at Cleveland Medical Center Cleveland Clinic is one of the world’s most renowned medical institutions, founded on February 28, 1921. In the 2017-2018 ranking of the best hospitals in the United States, Cleveland Clinic ranked second overall, only behind Mayo Clinic. Among them, cardiac surgery and urology are ranked first in the United States; General surgery, rheumatology, and nephrology rank second. Dr. Matthew Crowe is from Cleveland Medical Center. According to the official website of the Cleveland Clinic, Dr. Matthew Crowe is the Vice President of Innovation and Technology ...
Recently, the “Maidong Technology Park”, which is the global headquarters base of Mindray Animal Medical, officially started construction in Longhua, Shenzhen. It is reported that the land for the Maidong Technology Park project will be sold in September 2023, covering an area of 58600 square meters and a building area of 176000 square meters. The total planned investment is 1.774 billion yuan. After completion, it will create an intelligent manufacturing “black light” factory with high-precision automation equipment covering the entire area. Through automatic and intelligent on-site logistics scheduling, efficient, high-quality, and low-cost manufacturing will be achieved. 01. Expected annual output value exceeds 12 billion In recent years, Mindray Medical has begun to focus on four emerging businesses, namely animal medicine, minimally invasive surgery, orthopedics, and AED, on the basis of its traditional three core businesses. In 2022, Li Xiting, Chairman of Mindray Medical, made a statement Animal medicine is a ...
Recently, the National Medical Insurance Administration reported on the unannounced inspection of Wuxi Hongqiao Hospital in Jiangsu Province, and made it clear that the next step will be to guide the Jiangsu Provincial Medical Insurance Administration to conduct a comprehensive investigation in the local area. At the same time, it will organize a special action to severely crack down on fraud and insurance fraud across the country to focus on rectifying the unhealthy trends and corruption problems around the people in the medical insurance field. On October 10, the State Drug Administration issued the “Notice on Rewarding Internal Whistleblowers on Drug and Medical Device Quality and Safety (Draft for Comments)” (hereinafter referred to as the “Reward for Reporting”) for public comments. The “Reward for Reporting” clearly states that the announcement applies to reporting major violations of drug and medical device quality and safety to the drug supervision and management department, ...
Recently, the website of the State Intellectual Property Office updated a new invention patent, named “Method for controlling stimulator, stimulator, brain-computer interface system and chip”, and the inventor of the patent is Huawei Technologies Co., Ltd. It is reported that this is Huawei’s second brain-computer interface related patent. As early as June 2023, Huawei announced a patent called “A brain-computer interface device and information acquisition method”. Brain-computer interface is one of the most popular phenomenal technologies in recent years, and its potential in the medical field is highly expected by the industry. According to McKinsey’s calculations, the potential market size of global brain-computer interface medical applications is expected to reach US$40 billion in 2030, and it is expected to exceed the US$145 billion mark by 2040. With the increase in R&D investment, the medical application of brain-computer interface has gradually shifted from early abstract concepts to landing results. In September, ...
On October 15, Yaoshibang issued an announcement that it had signed a transaction agreement to acquire 100% of the equity of Yikuai Pharmaceutical, with a total consideration of RMB 1.035 billion, including a cash consideration of RMB 420 million and a share consideration of RMB 615 million. In the pharmaceutical industry, where mergers and acquisitions are common, this transaction with a total price of RMB 1 billion has attracted considerable attention. The reason is that this is not only the first large-scale acquisition of Yaoshibang, a pharmaceutical B2B e-commerce unicorn, since its listing, but also related to Yaoshibang’s own financial situation. Amid the tightening of listing, Yaoshibang successfully rang the bell on the Hong Kong Stock Exchange in June 2023. However, as a “digital enterprise that deeply cultivates the outpatient market” that went public at a loss, Yaoshibang had just turned a profit when it handed in its full-year performance ...
On October 15th, Hologic Corporation (hereinafter referred to as Hologic) announced that it had reached a final acquisition agreement with Gynesonics for approximately $350 million (approximately RMB 2.5 billion). With this acquisition, Haoluo Jie will further expand its layout in women’s health products to consolidate its leading position in global women’s health. Acquiring innovative products The Gynesonics company acquired this time is an innovative women’s healthcare company headquartered in California, USA. Since its establishment in 2005, we have been committed to providing safe and effective minimally invasive treatment solutions for women with symptomatic uterine fibroids. The Sonata system, the core product of Gynesonics, is the world’s first and only FDA approved diagnostic intrauterine imaging device that can treat specific symptomatic uterine fibroids, including fibroids associated with severe menstrual bleeding, through the cervix. This is also the purpose of Haoluo Jie’s huge investment in acquisition. The Sonata system consists of ...
Novo Nordisk recently partnered with 10 Indian artificial intelligence (AI) startups, marking an important moment for the Indian AI ecosystem. The Danish company, best known for its weight loss drug Wegovy, is leveraging AI innovations to streamline operations and improve efficiency. The moves are part of the Danish drugmaker’s expansion plans for operations in Bangalore, which it opened 17 years ago. The center helps manage the vast amounts of data collected about the safety and effectiveness of its drugs, including clinical trial information and reports of potential side effects. One of the factors driving the move is that demand for obesity and diabetes-related drugs is expected to grow, especially as global attention to these health issues grows. By strategically positioning itself in India, one of the world’s largest markets for diabetes drugs, Novo Nordisk expects to meet the growing demand by increasing its production capacity. The partnership also has a ...
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.